Manufacturing of biopharmaceuticals and implications for biosimilars

Kidney and Blood Pressure Research

Volumn 30, Issue SUPPL. 1, 2007, Pages 6-8

  Wurm, Florian M ^a  

^a EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BIOLOGICAL PRODUCT; ETANERCEPT; GENERIC DRUG; INFLIXIMAB; RECOMBINANT ANTIBODY; RITUXIMAB; VIRUS VACCINE;

CANCER RISK; CHILD CARE; CONFERENCE PAPER; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG PURIFICATION; DRUG STRUCTURE; EXPRESSION VECTOR; HUMAN; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BIOPHARMACEUTICS; CHEMISTRY, PHARMACEUTICAL; DRUG INDUSTRY; DRUGS, GENERIC; HUMANS;

EID: 34548152719     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107094     Document Type: Conference Paper

References (4)

1. Wurm FM: Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 2004;22:1393-1398.
2. Kao F-T, Puck TT: Genetics of somatic mammalian cells. IV. Properties of Chinese hamster cell mutants with respect to the requirement for proline. Genetics 1967;55:513.
3. Urlaub G, Kas E, Carothers AM, Chasin LA: Deletion of the diploid dihydrofolate reductase locus from cultured mammalian cells. Cell 1983;33:405-412.
4. The Report Immunization Safety Review: SV40 Contamination of Polio Vaccine and Cancer is available on the Internet at http://www.nap.edu.